RxGen employs multiple models to assess drug efficacy and validate therapeutic targets:

Ophthalmic

• Wet age-related macular degeneration
  • Laser-induced choroidal neovascularization

• Glaucoma
  • IOP modulation

• Uveitis
  • Immunogen induced uveitis

• Myopia
  • Form-deprivation myopia

• Cataract
  • Phacoemulsification surgical models

• Ocular Pharmacokinetics and Toxicology
  • Topical, punctal, subconjuntival, intravitreal, systemic

CNS

• Parkinson’s disease
  • MPTP model
  • Idiopathic Parkinson’s disease
  • L-dopa induced dyskinesias

• Schizophrenia
  • PCP model of cognitive impairment

• Dystonia
  • Neuroleptic sensitization

• Alzheimer’s disease
  • Abeta plaque formation in older cohorts

• Spinal cord injury
  • Cord hemisection model

Metabolic

• Obesity
  • Diet-induced obesity
  • Naturally obese cohorts

• Dyslipidemia
  • Diet-induced lipid profile modulation
  • Selection of naturally variant phenotypes

• Diabetes
  • Obesity associated insulin resistance

Women’s Health

• Endometrial safety
  • Endometrial tolerance of hormone therapies

• Osteoporosis
  • Bone density in aged and/or ovariectomized females

Immunology

• Antigen challenge
• Adjuvant and vaccine evaluations

Surgical models

• Surgical disease models
• Device implantation